Enterocolitis

Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

Retrieved on: 
Thursday, February 29, 2024
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Investigational New Drug, Enterocolitis, Inflammatory Bowel Diseases, Drug development, UQAM, Pediatrics, Life, Ipsen, Therapy, Patient, Intellectual property, IND, Gastroenterology, Partnership, Pharmaceutical industry

Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.

Key Points: 
  • Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.
  • Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions.
  • Maxime Ranger, President and CEO of Neurenati Therapeutics commented, “Currently, surgery remains the only option to newborns with HSCR.
  • As fourth member of the Board, he joins Rodolphe Soret (cofounder), Benoit Doré (Axelys), and Maxime Ranger (Neurenati).

Biosimilar Lymphocyte Modulator Global Market Report 2022: Featuring Pfizer, Biogen, Genentech, Novartis & Celltrion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Health, General Health, Multiple myeloma, Immunotherapy, TILS, TALEN, Radiation, Breast cancer, Psoriasis, Approximation error, Enterocolitis, Lymphoma, George Washington University School of Medicine & Health Sciences, TIL, Disease, Washington University School of Medicine, Leukemia, Biosimilar, Methotrexate, CLL, USFDA, Society, Immune system, Alemtuzumab, Physician, Arthritis, Lymphatic system, Efalizumab, Diabetes, Growth, Multiple sclerosis, Etoposide, Patient, Health, Generic drug, Pharmaceutical industry, Cellectis

The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The main types of drugs in biosimilar lymphocyte modulator are campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar.
  • The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others
    Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market.
  • The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market.

Global Oral Biologics & Biosimilar Drugs Markets, 2016-2021, 2021-2026F, 2031F: Lymphocyte Modulators, Interleukin Inhibitors, & Tumor Necrosis Factor-Alpha Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Pharmaceutical, Molecule, Diabetes, Disease, Food, Alzheimer's disease, Sarcoma, Government, Crohn's disease, Cell, Roche, EMA, Allergan, Monocyte, Immune system, Cancer, Prevalence, AstraZeneca, Novo Nordisk, Therapy, Cytokine, Multiple sclerosis, Insulin, HIV/AIDS, GlaxoSmithKline, Growth, Biosimilar, United Nations, Sanofi, US Foods, Eli Lilly and Company, Vaccine, Concord Biotech, Macrophage, Novartis, Arthritis, Carcinoma, European Medicines Agency, Distribution, Protein, Lundbeck, Multiple myeloma, Conditional sentence, Asthma, Psoriasis, Peptide, Technology, Lymphocyte, Enterocolitis, Interleukin, Pharmacy, Pharmaceutical industry, Generic drug, Dietary supplement, Food and Drug Administration Safety and Innovation Act

Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

Key Points: 
  • Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.
  • The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.
  • The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
  • The main therapy types of are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors.

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

Retrieved on: 
Monday, March 28, 2022
Private Securities Litigation Reform Act, Journal, Synthetic, Plasma, SOC, NYSE, Primary tumor, Synthetic biological circuit, MTD, Enterocolitis, SEC, IAP, Time, GLOBE, CD8, AES, Degenerative disease, Annual report, Immunotherapy, IV, Population, Sale, Marketing, Liver disease, CDI, Thrombocytopenia, Toxic leukoencephalopathy, Terminology, CGMP, Therapy, AMR, III, Clinical trial, Growth, DLT, IL-6, AE, HCT, Patient, SYN, Company, VCN, Neoplasm, Index (publishing), Neutropenia, Director general, Clostridioides difficile infection, Maintenance, Acquisition, Pharmaceutical industry, Medical imaging, Part Two, Fever, Part, Cancer

ROCKVILLE, Md., March 28, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the peer-reviewed publication of a Phase 1, multicenter, open-label, dose-escalation study investigating the therapeutic potential of intravenous VCN-01 oncolytic adenovirus with or without standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) in patients with advanced solid tumors. The data, published in the Journal for ImmunoTherapy of Cancer, suggests that treatment with VCN-01 is feasible and has an acceptable safety profile, with encouraging biological and clinical activity. These findings provide valuable dose-finding context and inform the clinical development strategy for VCN-01.

Key Points: 
  • The data, published in the Journal for ImmunoTherapy of Cancer, suggests that treatment with VCN-01 is feasible and has an acceptable safety profile, with encouraging biological and clinical activity.
  • More broadly, these results will help guide our rapidly advancing clinical program for VCN-01 and further support the development of our novel OV platform.
  • The objective was to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.

Biosimilar Lymphocyte Modulator Global Market Report 2021 Featuring Pfizer, Biogen, Genentech, Novartis, and Celltrion - ResearchAndMarkets.com

Retrieved on: 
Friday, December 10, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health, TILS, Arthritis, Radiation, Immunotherapy, Breast cancer, Technology, Lymphoma, Psoriasis, Lymphatic system, TIL, Enterocolitis, Degenerative disease, COVID-19, Methotrexate, Approximation error, Modulation, Washington University School of Medicine, Iovance Biotherapeutics, USFDA, Multiple sclerosis, Biosimilar, Patient, George Washington University School of Medicine & Health Sciences, Growth, Novartis, Cancer, Physician, Immune system, Biogen, Multiple myeloma, Efalizumab, Association, Organization, Leukemia, Etoposide, TALEN, Society, Pfizer, Celltrion, Diabetes, Human, Disease, Fine chemical, Pharmaceutical industry

The "Biosimilar Lymphocyte Modulator Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Lymphocyte Modulator Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar lymphocyte modulator market consists of sales of immune regulating lymphocyte modulators by entities (organizations, sole traders and partnerships) that manufacture lymphocyte modulator biosimilars.
  • The biosimilar lymphocyte modulator market covered in the report is segmented by drug into campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar and by disease into arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others.
  • The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market.

PD-1 Resistant Head and Neck Cancer (HNC) Market Insights, Epidemiology and Forecast 2030: Focus on Germany, France, Italy, Spain, United Kingdom, Japan, China, South Korea, and Taiwan - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Pharmaceutical, Health, Oncology, ICIS, Immune tolerance, Lymphatic system, Ipilimumab, PD-1, Ira Pastan, Cancer, Technology, IPH2201, Immunosuppression, Epidemiology, II, BKM120, HNC, NK, Overalls, United Kingdom, News, Patient, Novartis, Table, Enterocolitis, Comprehension, III, Buparlisib, ICI, Palladium, Pharmaceutical industry, Vaccine

The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
  • The report also covers current PD-1 Resistant Head and Neck Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities.
  • The epidemiology segment also provides the PD-1 Resistant Head and Neck Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan.
  • The PD-1 Resistant Head and Neck Cancer report's drug chapter segment encloses the detailed analysis of PD-1 Resistant Head and Neck Cancer's early-stage (Phase I, II, and III) pipeline drugs.

Global Checkpoint Inhibitor Refractory Cancer Market Insights, Epidemiology and Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 17, 2021
Health, Pharmaceutical, Cancer, Immune tolerance, Incidence, Ipilimumab, Ira Pastan, Immune system, Survival, Checkpoint, Chromatin, HDAC, II, Overalls, News, Patient, Enterocolitis, III, Cytokine, ICI, Pharmaceutical industry, Uranium, Vaccine

The "Checkpoint Inhibitor Refractory Cancer - Market Insights, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Checkpoint Inhibitor Refractory Cancer - Market Insights, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Checkpoint-inhibitor Refractory Cancer - Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the Checkpoint-inhibitor Refractory Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint-inhibitor Refractory Cancer symptoms epidemiology segmented as the Incidence by tumor type, Checkpoint-inhibitor treated patients and Checkpoint-inhibitor refractory patients.
  • The Checkpoint-inhibitor Refractory Cancer report's drug chapter segment encloses the detailed analysis of Checkpoint-inhibitor Refractory Cancer early-stage (Phase- I, II, and III) pipeline drugs.

Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Biotechnology, Pharmaceutical, Health, Growth, Peptide, Arthritis, Alzheimer's disease, AstraZeneca, EMA, Food, Prevalence, Enterocolitis, Novartis, Vaccine, Sarcoma, Crohn's disease, COVID-19, Insulin, Therapy, Technology, Disease, Pharmacy, Partnership, Psoriasis, Multiple myeloma, Cancer, Diabetes, Biosimilar, Mylan, Conditional sentence, Eli Lilly and Company, Carcinoma, Biocon, European Medicines Agency, Asthma, Asia, Allergan, HIV/AIDS, Protein, Novo Nordisk, Multiple sclerosis, Government, US Foods, Insulin glargine, Pharmaceutical industry, Generic drug

The "Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.
  • The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
  • North America was the largest region in the global oral biologics & biosimilar drugs market, accounting for 46% of the market in 2019.

ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml

Retrieved on: 
Thursday, June 20, 2019
RTT, Medical specialties, Medicine, Infectious diseases, Eli Lilly and Company, Antibiotic-resistant bacteria, Total synthesis, Vancomycin, Clostridioides difficile, Enterocolitis, Fidaxomicin, Glycopeptide antibiotic

BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml, indicated for the treatment of various infections.

Key Points: 
  • BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml, indicated for the treatment of various infections.
  • ANI acquired the ANDA for Vancomycin for Oral Solution in 2014 in an acquisition that included the NDA for Vancocin 125 mg and 250 mg capsules and approved ANDAs for Vancomycin Hydrochloride Injection 500 mg, 1 gm and 10 gm.
  • Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP

Retrieved on: 
Wednesday, May 1, 2019
RTT, Medical specialties, Medicine, Infectious diseases, Vancomycin, Clostridioides difficile, Enterocolitis

The parenteral form of Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis.

Key Points: 
  • The parenteral form of Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis.
  • Parenteral administration of Vancomycin Hydrochloride alone is of unproven benefit for these indications.
  • According to IQVIA, US sales of Vancomycin Hydrochloride for Injection, USP, 5g, 10g and 750mg were approximately $247 million in the 12 months ending February 2019.
  • Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of 100 products.